Michael Gent

53.8k total citations · 22 hit papers
230 papers, 34.9k citations indexed

About

Michael Gent is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Michael Gent has authored 230 papers receiving a total of 34.9k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Cardiology and Cardiovascular Medicine, 105 papers in Internal Medicine and 61 papers in Surgery. Recurrent topics in Michael Gent's work include Venous Thromboembolism Diagnosis and Management (105 papers), Atrial Fibrillation Management and Outcomes (59 papers) and Antiplatelet Therapy and Cardiovascular Diseases (40 papers). Michael Gent is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (105 papers), Atrial Fibrillation Management and Outcomes (59 papers) and Antiplatelet Therapy and Cardiovascular Diseases (40 papers). Michael Gent collaborates with scholars based in Canada, United States and United Kingdom. Michael Gent's co-authors include Jack Hirsh, Stuart J. Connolly, Robin S. Roberts, Mark N. Levine, John A. Cairns, J. Hirsh, Jim A. Julian, David L. Sackett, Randall T. Higashida and Howard A. Rowley and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Michael Gent

227 papers receiving 32.3k citations

Hit Papers

Intra-arterial Prourokinase for Acute Ischem... 1974 2026 1991 2008 1999 2003 1995 2000 1998 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Intra-arterial Prourokinase for Acute Ischemic Stroke
    1999 2.2k citations Michael Gent et al. profile →
  2. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
    2003 1.8k citations Mark N. Levine, Ross Baker et al. profile →
  3. Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
    1995 1.7k citations Mark N. Levine, Jack Hirsh et al. profile →
  4. Canadian Implantable Defibrillator Study (CIDS)
    2000 1.0k citations Stuart J. Connolly, Michael Gent et al. Circulation profile →
  5. PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke
    1998 900 citations Michael Gent et al. profile →
  6. Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction
    2004 894 citations Paul Dorian, Robin S. Roberts et al. profile →
  7. A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
    1996 872 citations Michael Gent, Jack Hirsh et al. profile →
  8. Canadian atrial fibrillation anticoaguiation (CAFA) study
    1991 831 citations Stuart J. Connolly, Andreas Laupacis et al. Journal of the American College of Cardiology profile →
  9. Aspirin, Sulfinpyrazone, or Both in Unstable Angina
    1985 778 citations John A. Cairns, Michael Gent et al. profile →
  10. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    2009 741 citations Michael R. Lassen, Kenneth A. Bauer et al. The Lancet profile →
  11. Platelet-Active Drugs
    2001 717 citations Carlo Patrono, Barry S. Coller et al. CHEST Journal profile →
  12. THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE
    1989 616 citations Michael Gent et al. The Lancet profile →
  13. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
    1997 607 citations John A. Cairns, Stuart J. Connolly et al. The Lancet profile →
  14. A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome
    2003 591 citations Mark Crowther, Jeff Ginsberg et al. profile →
  15. Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis
    1982 560 citations J. Hirsh, Michael Gent et al. profile →
  16. Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis
    1986 560 citations Jack Hirsh, William Geerts et al. profile →
  17. Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis
    2000 550 citations Michael Gent, Jeff Ginsberg et al. Journal of Clinical Oncology profile →
  18. Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
    2003 544 citations Clive Kearon, Jeffrey S. Ginsberg et al. profile →
  19. Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis
    1979 457 citations Edward Genton, Jack Hirsh et al. profile →
  20. Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset
    1984 428 citations C. R. Stiller, John Dupré et al. profile →
  21. Adjusted Subcutaneous Heparin versus Warfarin Sodium in the Long-Term Treatment of Venous Thrombosis
    1982 340 citations Jack Hirsh, Edward Genton et al. profile →
  22. The Burlington Randomized Trial of the Nurse Practitioner
    1974 334 citations Robin S. Roberts, Michael Gent et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Gent Canada 90 20.2k 16.1k 9.1k 5.7k 5.1k 230 34.9k
Jack Hirsh Canada 96 22.7k 1.1× 22.3k 1.4× 13.3k 1.5× 2.8k 0.5× 8.2k 1.6× 350 38.4k
Sam Schulman Canada 69 21.5k 1.1× 21.5k 1.3× 7.1k 0.8× 3.6k 0.6× 7.7k 1.5× 501 34.5k
Mark Crowther Canada 93 19.7k 1.0× 21.4k 1.3× 10.3k 1.1× 4.0k 0.7× 9.2k 1.8× 584 40.0k
Harry R. Büller Netherlands 92 18.6k 0.9× 24.6k 1.5× 8.6k 0.9× 3.5k 0.6× 8.2k 1.6× 450 35.7k
Menno V. Huisman Netherlands 76 15.5k 0.8× 20.0k 1.2× 5.8k 0.6× 3.3k 0.6× 3.2k 0.6× 469 29.6k
Martin H. Prins Netherlands 90 17.7k 0.9× 19.9k 1.2× 8.9k 1.0× 2.9k 0.5× 6.8k 1.3× 384 34.7k
John A. Heit United States 68 15.2k 0.8× 23.7k 1.5× 9.3k 1.0× 2.5k 0.4× 6.5k 1.3× 220 30.9k
Samuel Z. Goldhaber United States 100 27.6k 1.4× 35.0k 2.2× 10.6k 1.2× 6.6k 1.2× 5.4k 1.1× 614 47.4k
John W. Eikelboom Canada 94 35.1k 1.7× 18.4k 1.1× 9.4k 1.0× 5.6k 1.0× 4.0k 0.8× 670 47.6k
Frits R. Rosendaal Netherlands 101 11.3k 0.6× 15.7k 1.0× 6.6k 0.7× 3.2k 0.6× 18.9k 3.7× 806 41.4k

Countries citing papers authored by Michael Gent

Since Specialization
Citations

This map shows the geographic impact of Michael Gent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Gent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Gent more than expected).

Fields of papers citing papers by Michael Gent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Gent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Gent. The network helps show where Michael Gent may publish in the future.

Co-authorship network of co-authors of Michael Gent

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Gent. A scholar is included among the top collaborators of Michael Gent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Gent. Michael Gent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Laskin, Carl A., Karen A. Spitzer, Christine A. Clark, et al.. (2009). Low Molecular Weight Heparin and Aspirin for Recurrent Pregnancy Loss: Results from the Randomized, Controlled HepASA Trial. The Journal of Rheumatology. 36(2). 279–287. 230 indexed citations
2.
Turpie, Alexander G.G., Michael R. Lassen, Ajay K. Kakkar, et al.. (2009). POOLED ANALYSIS OF FOUR STUDIES OF RIVAROXABAN: EFFECT ON SYMPTOMATIC EVENTS AND BLEEDING AND THE INFLUENCE OF CLINICALLY RELEVANT PATIENT SUBGROUPS. CHEST Journal. 136(4). 144S–144S. 3 indexed citations
3.
Monagle, Paul, Andrew Cochrane, Robin Roberts, et al.. (2008). Abstract 1157: A Multicentre Randomized Trial Comparing Heparin/warfarin Versus Aspirin As Primary Thromboprophylaxis For Two Years After Fontan Procedure In Children. Circulation. 118. 1 indexed citations
4.
Eriksson, Bengt I., Kenneth A. Bauer, Lars C. Borris, et al.. (2007). Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. Thrombosis and Haemostasis. 97(6). 931–937. 56 indexed citations
5.
Kearon, Clive, Jeffrey S. Ginsberg, James D. Douketis, et al.. (2006). An Evaluation of D-Dimer in the Diagnosis of Pulmonary Embolism. Annals of Internal Medicine. 7 indexed citations
6.
Büller, H. R., et al.. (2005). Fondaparinux ou enoxaparin pour le traitement initial de la thrombose veineuse profonde symptomatique. Un essai randomisé. La Revue de Médecine Interne. 26(1). 82–83. 2 indexed citations
7.
Newman, David, Ching Lau, Anthony Tang, et al.. (2003). Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. American Heart Journal. 145(3). 430–437. 66 indexed citations
8.
Baker, Ross, C.L. Bowden, AK Kakkar, et al.. (2002). A Randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE).. Blood. 100(11). 13 indexed citations
9.
Patrono, Carlo, Barry S. Coller, James E. Dalen, et al.. (1998). The Relationships Among Dose, Effectiveness, and Side Effects. CHEST Journal. 114(5). 17 indexed citations
10.
Bousser, Marie‐Germaine, Robert Roberts, & Michael Gent. (1997). Ticlopidine and Clopidogrel in Secondary Stroke Prevention. Cerebrovascular Diseases. 7(6). 17–23. 8 indexed citations
11.
Gent, Michael, J. Hirsh, JS Ginsberg, et al.. (1996). Low-Molecular-Weight Heparinoid Orgaran Is More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip Fracture. Circulation. 93(1). 80–84. 83 indexed citations
12.
Rajan, R., Amiram Gafni, Mark N. Levine, J. Hirsh, & Michael Gent. (1995). Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation.. Journal of Clinical Oncology. 13(1). 42–46. 31 indexed citations
13.
Levine, Mark N., J. Hirsh, Michael Gent, et al.. (1994). Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. The Lancet. 343(8902). 886–889. 400 indexed citations
14.
Connolly, Stuart J., Andreas Laupacis, Michael Gent, et al.. (1991). Canadian atrial fibrillation anticoaguiation (CAFA) study. Journal of the American College of Cardiology. 18(2). 349–355. 831 indexed citations breakdown →
15.
Morgan, Christopher D., Robin S. Roberts, Aminul Haq, et al.. (1991). Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. Journal of the American College of Cardiology. 17(7). 1451–1457. 26 indexed citations
16.
Tugwell, Peter, Claire Bombardier, Michael Gent, et al.. (1990). Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. The Lancet. 335(8697). 1051–1055. 182 indexed citations
17.
Stiller, C. R., John Dupré, Michael Gent, et al.. (1987). Effects of cyclosporine in recent-onset juvenile type 1 diabetes: Impact of age and duration of disease. The Journal of Pediatrics. 111(6). 1069–1072. 20 indexed citations
18.
Barnett, H. J. M., Michael Gent, D L Sackett, & D. Wayne Taylor. (1979). Reply. Annals of Neurology. 5(6). 599–601. 2 indexed citations
19.
La, Harker, J. Hirsh, Michael Gent, & Edward Genton. (1975). Critical evaluation of platelet-inhibiting drugs in thrombotic disease.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 9. 229–54. 9 indexed citations
20.
Hamilton, William F., K.N.V. Palmer, & Michael Gent. (1970). Expectorant Action of Bromhexine in Chronic Obstructive Bronchitis. BMJ. 3(5717). 260–261. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jack Hirsh Breakdown of academic impact, for papers by Sam Schulman Breakdown of academic impact, for papers by Mark Crowther Breakdown of academic impact, for papers by Harry R. Büller Breakdown of academic impact, for papers by Menno V. Huisman Breakdown of academic impact, for papers by Martin H. Prins Breakdown of academic impact, for papers by John A. Heit Breakdown of academic impact, for papers by Samuel Z. Goldhaber Breakdown of academic impact, for papers by John W. Eikelboom Breakdown of academic impact, for papers by Frits R. Rosendaal
Rankless by CCL
2026